Publicly traded companies that have been heavily involved in developing therapies and vaccines for Covid-19 have experienced significant spikes in their stock prices from March 2020 to January 2021, including Germany’s BioNTech, which surged 187% in one year.
If you are not happy with the results below please do another search
50 search results for:
When it comes to matters of heart health, no amount of exercise is too much, scientists said regarding research that debunks the myth that high levels of vigorous physical activity might not always be beneficial.
SubjectWell – the largest risk-free clinical trials marketplace – released statistics on patients’ attitudes toward clinical research, specifically those with liver diseases.
The advancing rollout of approved Covid-19 vaccines provides hope to many that existing lockdowns and social restrictions will soon be lifted, but experts suggest a “return to normal” likely will not occur until herd immunity is achieved.
Despite some controversy over the effectiveness of Gilead Sciences’ Veklury (remdesivir) as the first antiviral drug approved to treat Covid-19, the product is bolstering the company’s bottom line and 2020 guidance was updated to reflect that.
Gene therapy is a fast-growing industry. Though demand for its products – including pDNA, AAV, retrovirus, lentivirus and others – has significantly increased over the last 10 years, production challenges have remained unresolved.
Enalare Therapeutics Inc., dedicated to developing novel therapies for patients suffering from acute respiratory conditions, announced the completed formation of the clinical stage biopharmaceutical company’s scientific advisory board.
The Trump administration plans to release Covid-19 vaccine doses it had been holding back for second shots and will urge states to offer them to all Americans over age 65, according to U.S. Department of Health and Human Services Secretary Alex Azar.
Biond Biologics Ltd. forged an exclusive global license agreement, potentially worth more than $1 billion, with French drugmaker Sanofi for the development and commercialization of the Israeli company’s BND-22 cancer drug.
British drugmaker GSK and U.S.-based Vir Biotechnology will evaluate a second antibody-based treatment in patients with mild to moderate Covid-19 in an early-stage to mid-stage trial.